USOO5932227A United States Patent (19) 11 Patent Number: 5,932,227 Higo et al. (45) Date of Patent: Aug. 3, 1999 54). PERCUTANEOUSLY ADMINISTRABLE BASE 56) References Cited COMPOSITION AND DRUG COMPOSITION PREPARED THEREFROM U.S. PATENT DOCUMENTS 75 Inventors: Naruhito Higo; Yukio Kojima; 4,082,881 4/1978 Chen et al. ............................. 424/241 Ken-ichi Komori, all of Ibaragi, Japan 4.552,872 11/1985 Cooper et al. .......................... 514/175 5,254,348 10/1993 Hoffmann et al. ...................... 424/449 73 Assignee: Hisamitsu Pharmaceutical Co., Inc., 5,571,530 11/1996 Nakano et al. ......................... 424/448 Saga, Japan 21 Appl. No.: 08/374,603 Primary Examiner Thurman K. Page 22 PCT Filed: Jul. 23, 1993 ASSistant Examiner William E. Benston, Jr. e a? as Attorney, Agent, or Firm Wenderoth, Lind & Ponack, 86 PCT No.: PCT/JP93/01034 LLP S371 Date: Mar. 29, 1995 57 ABSTRACT S 102(e) Date: Mar. 29, 1995 A percutaneously administrable base composition which 87 PCT Pub. No.: WO94/02119 facilitates the percutaneous absorption of drugs and is remarkably reduced in the irritancy against the skin. The PCT Pub. Date: Feb. 3, 1994 composition comprises 10-60 wt.% of lower alcohol, 10-50 30 Foreign Application Priority Data wt.% of humectant, 10–70 wt.% of water, 0.1-15 wt.% of Jul. 23, 1992 JP J 4-218369 abirritant and 0.1-15 wt.% of absorption promoter. A drug Aug.ul. Z, 4, 1992 JP JapanaPail ..................................... , composition is prepared by adding to the above composition various active ingredients Such as antituSSive, expectorant, (51) Int. Cl." ....................................................... A61K 9/08 skeletal muscle relaxant, antivertiginous drug, narcotic, drug 52 U.S. Cl. ............................................. 424/401; 424/449 for the circulatory System, and So forth. 58 Field of Search ..................................... 424/448, 449, 424/241, 489, 452, 455; 514/772.4 18 Claims, No Drawings 5,932.227 1 2 PERCUTANEOUSLY ADMINISTRABLE BASE Under Such circumstances, these percutaneous adminis COMPOSITION AND DRUG COMPOSITION tration methods cannot provide Sufficient practical merits for PREPARED THEREFROM use of a drug, and are not therefore as yet Satisfactory in drug Stability for pharmaceutical purposes, as absorption and low This application is a 371 of PCT/JP 93/01034 filed Jul. 5 irritation to Skin, and manifestation of drug efficacy. 23, 1993. AS the example, tulobuterol is a B-stimulant drug having Selectively a bronchiectasis function and is known as a FIELD OF THE INVENTION therapeutic drug of bronchial asthma, chronic bronchitis, The present invention relates to a irritation percutaneously and dyspnea caused by airway obliteration disease. This is in administrable base composition which increases percutane general orally administered in the form of tablets or dry ous absorption of a drug and has a low irritation against Skin, syrup. Orally administered tulobuterol drug has the problem and a drug composition prepared therefrom. of Such adverse Side effects as palpitation, defect of circu latory System like increase in cardiac rate, headache, BACKGROUND OF THE INVENTION excitement, defect of psycho-nervous System like giddineSS and defect of gastric-intestinal disorder like Vomiting, AS conventional drug administration method, oral 15 administration, rectal administration, intracutaneous anorexia, and other troubles in the psycho-nervous System, administration, and intravenous administration are generally and vomiting, anorexia and other troubles in the gastric known. Especially oral administration is popularly adopted system. These side effects are considered to attribute to the temporary increase in the drug concentration in blood after among others. Oral administration has been defective in that oral administration. Continuity of the function is still insuf the liver is Susceptible to primary metabolism after absorp ficient in oral drug, and a paroxysm occurring frequently at tion of the drug, and a higher blood concentration of drug peep of dawn cannot Sufficiently be coped with. AS a than the necessary level is observed temporarily after oral measure to overcome these defects, therefore, there is a administration. Furthermore, many cases of gastrointestinal demand for a drug composition permitting a long endurance trouble, feeling of Vomiting, anorexia and other side effects of the tulobuterol concentration in blood through percuta are reported. 25 neous administration, and for this purpose, an external-use Recently, therefore, with a view to Solving these defects drug for percutaneously administering tulobuterol has been of oral administration, the method of percutaneous admin proposed (Japanese Patent Provisional Publication No. istration is attracting the general attention as permitting 63-10,716). The intent of the patent is to prevent temporary absorption of a drug safely and continuously. Efforts have increase in the concentration in blood after administration of been made to develop external-use drugs for this purpose, the drug by using a cream or patch as new method. For the and Some products have already been put to the market. purpose of promoting percutaneous absorption, there can be In the drugs for Such percutaneous administration, cited a method of having a composition comprising a lower however, percutaneous absorption of the drug is still on a alcohol, an alcohol having a carbon number of from 7 to 20 low level in many cases, and the object seems to be far from or an aliphatic hydrocarbon having a carbon number of from fully being achieved. 35 5 to 30, and water contain effective ingredients (Japanese More particularly, normal skin has originally a barrier Patent Provisional Publication No. 61-249,934). This pub function of preventing ingression of an eXenobiotic Sub lication discloses applicability of the composition in the stance into the body. A base alone used for ordinary percu form of ointment, plaster, lotion, adhesive tape impregnated taneous administration cannot therefore ensure Sufficient form and gel. A transdermal matrix based on a composition percutaneous absorption of effective ingredients blended 40 comprising polyisobutylene which is a Synthetic rubber and therein. It is therefore necessary to make contrivances to tulobuterol which is an effective ingredient is also proposed improve percutaneous absorption of a drug by controlling (Japanese Patent Provisional Publication No. 4-99,720). the barrier function of the horny Substance layer of skin. For However, these conventional methods and compositions this purpose, blending of a material known as percutaneous therefore cannot as yet be Sufficient in Stability of drug absorption promoter into the base is generally attempted. 45 absorption and irritation to skin, and drug pharmacological For example, there have been proposed dimethyl acetamide a effects. combined with ethyl alcohol, isopropyl alcohol or myristyl These circumstances are not limited to above-mentioned alcohol as an absorption promoter in combination with a case of tulobuterol, but are problems common to various lower alkylamide (U.S. Pat. No. 3,472,931), a combination drugs in application. of 2-pyrrolidone, an appropriate oil, and a Straight-chain 50 The present invention was developed to solve the prob fatty acid with ester of alcohol (U.S. Pat. No. 4.017,641), lems in the prior art as described above, and has an object and a combination of a lower alcohol having a carbon to provide a base composition for percutaneous number of from 7 to 20, an aliphatic hydrocarbon having a administration, which increases percutaneous absorption of carbon number of from 5 to 30, an alcohol ester of aliphatic the drug, and has a low irritation to skin of the portion of carboxylic acid having a carbon number of from 19 to 26, 55 administration, and a drug composition for percutaneous mono- or di-ether having a carbon number of from 10 to 24, administration, using the above composition, excellent in and ketone having a carbon number of from 11 to 15 with stability. water (Japanese Patent Provisional Publication No. 61-249.934). DISCLOSURE OF THE INVENTION However, these conventional absorption promoter and 60 The present invention provides a percutaneously admin absorption promoting compositions cannot as yet be con istrable base composition which comprises from 10 to 60 wt. sidered to be sufficient in safety of skin. Percutaneous % of lower alcohol, from 10 to 50 wt.% of humectant from absorption enhancer composition with low irritation to skin 10 to 70 wt.% of water, from 0.1 to 15 wt.% of abirritant, (Japanese Patent Provisional Publication No. 2-115,131) has and from 0.1 to 15 wt.% of absorption promoter. been proposed. In this case also, irritation is observed on the 65 The present invention provides also a drug composition skin of the portion of administration of a Subject particularly for percutaneous administration containing a drug blended Sensitive to alcohol. into the above-mentioned base composition. 5,932.227 3 4 More specifically, by administering a drug contained in over 50 wt.%, or over 30 wt %, tends to cause a decrease the above-mentioned base composition comprising lower in skin penetration of the drug. When the concentration of alcohol, the humectant, water, the abirritant, and the absorp humectant is under 10 wt.%, or under 20 wt.%, irritation tion promoter, the drug in efficiently absorbed, and irritation to the Subject skin is observed in the drug composition. to the administered portion is alleviated.